A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in BRAF-Driven Pediatric Low-Grade Glioma Cells

Pilocytic astrocytomas as well as other pediatric low-grade gliomas (pLGG) exhibit genetic events leading to aberrant activation of the MAPK pathway. The most common alterations are KIAA1549:BRAF fusions and BRAFV600E and NF1 mutations. Novel drugs targeting the MAPK pathway (MAPKi) are prime candidates for the treatment of these single-pathway diseases. We aimed to develop an assay suitable for preclinical testing of MAPKi in pLGGs with the goal to identify novel MAPK pathway–suppressing synergistic drug combinations. A reporter plasmid (pDIPZ) with a MAPK-responsive ELK-1–binding element driving the expression of destabilized firefly luciferase was generated and packaged using a lentiviral vector system. Pediatric glioma cell lines with a BRAF fusion (DKFZ-BT66) and a BRAFV600E mutation (BT-40) background, respectively, were stably transfected. Modulation of the MAPK pathway activity by MAPKi was measured using the luciferase reporter and validated by detection of phosphorylated protein levels. A screening of a MAPKi library was performed, and synergy of selected combinations was calculated. Screening of a MAPKi library revealed MEK inhibitors as the class inhibiting the pathway with the lowest IC50s, followed by ERK and next-generation RAF inhibitors. Combination treatments with different MAPKi classes showed synergistic effects in BRAF fusion as well as BRAFV600E mutation backgrounds. Here, we report a novel reporter assay for medium- to high-throughput preclinical drug testing in pLGG cell lines. The assay confirmed MEK, ERK, and next-generation RAF inhibitors as potential treatment approaches for KIAA1549:BRAF and BRAFV600E-mutated pLGGs. In addition, the assay revealed that combination treatments synergistically suppressed MAPK pathway activity.

[1]  W. Sellers,et al.  Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. , 2020, Journal of medicinal chemistry.

[2]  G. Plowman,et al.  ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine , 2019, Molecular Cancer Therapeutics.

[3]  Robert L. Judson,et al.  Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses. , 2019, Cell reports.

[4]  C. von Kalle,et al.  Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains , 2019, Oncogene.

[5]  Sorafenib , 2019, Reactions Weekly.

[6]  David T. W. Jones,et al.  The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma , 2018, Clinical Cancer Research.

[7]  Tristan E. Knight,et al.  Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma , 2018, Pediatric blood & cancer.

[8]  S. Cook,et al.  ERK1/2 inhibitors: New weapons to inhibit the RAS‐regulated RAF‐MEK1/2‐ERK1/2 pathway , 2018, Pharmacology & therapeutics.

[9]  B. Taylor,et al.  A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor. , 2018, Cancer discovery.

[10]  C. Pratilas,et al.  Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study. , 2018 .

[11]  B. Geoerger,et al.  LGG-46. TRAMETINIB THERAPY IN PEDIATRIC PATIENTS WITH LOW-GRADE GLIOMAS (LGG) WITH BRAF GENE FUSION; A DISEASE-SPECIFIC COHORT IN THE FIRST PEDIATRIC TESTING OF TRAMETINIB , 2018, Neuro-Oncology.

[12]  Joshua M. Korn,et al.  Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF. , 2018, Cancer research.

[13]  B. Agianian,et al.  Current Insights of BRAF Inhibitors in Cancer. , 2018, Journal of medicinal chemistry.

[14]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[15]  Lily Shao,et al.  Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors , 2017, PloS one.

[16]  Ying Cheng,et al.  Current Development Status of MEK Inhibitors , 2017, Molecules.

[17]  Paul Shapiro,et al.  Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib) , 2017, Molecular Cancer Therapeutics.

[18]  M. Prados,et al.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.

[19]  W. Hahn,et al.  A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas , 2017, Neuro-oncology.

[20]  David T. W. Jones,et al.  Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing , 2016, Oncotarget.

[21]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[22]  James Tsai,et al.  RAF inhibitors that evade paradoxical MAPK pathway activation , 2015, Nature.

[23]  S. Cook,et al.  MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road , 2015, Nature Reviews Cancer.

[24]  Xiwen Ma,et al.  Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers. , 2015, Cancer cell.

[25]  L. Garraway,et al.  Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors , 2015, Molecular Cancer Therapeutics.

[26]  Mickael Guedj,et al.  Analysis of drug combinations: current methodological landscape , 2015, Pharmacology research & perspectives.

[27]  M. Kool,et al.  Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma , 2015, Acta neuropathologica communications.

[28]  S. Puget,et al.  Long-term functional outcome of patients with cerebellar pilocytic astrocytoma surgically treated in childhood , 2015, Brain injury.

[29]  David T. W. Jones,et al.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. , 2014, Neuro-oncology.

[30]  Christof Fellmann,et al.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. , 2014, Cancer cell.

[31]  Luhua Lai,et al.  Synergistic and Antagonistic Drug Combinations Depend on Network Topology , 2014, PloS one.

[32]  M. Holderfield,et al.  Mechanism and consequences of RAF kinase activation by small-molecule inhibitors , 2014, British Journal of Cancer.

[33]  N. André,et al.  Outcome analysis of childhood pilocytic astrocytomas: a retrospective study of 148 cases at a single institution , 2013, Neuropathology and applied neurobiology.

[34]  Wei Xu,et al.  Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma. , 2013, Cell reports.

[35]  Kaitlyn Le,et al.  Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells , 2013, Pigment cell & melanoma research.

[36]  Roland Eils,et al.  Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma , 2013, Nature Genetics.

[37]  Heather L. Mulder,et al.  Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.

[38]  A. Resnick,et al.  Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas , 2013, Proceedings of the National Academy of Sciences.

[39]  M. Pawlita,et al.  High‐throughput SNP‐based authentication of human cell lines , 2013, International journal of cancer.

[40]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[41]  K. Flaherty,et al.  Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.

[42]  T. Pietsch,et al.  Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology. , 2012, Neuro-oncology.

[43]  A. von Deimling,et al.  Distinct requirement for an intact dimer interface in wild‐type, V600E and kinase‐dead B‐Raf signalling , 2012, The EMBO journal.

[44]  Ru Zhang,et al.  Tools for GPCR drug discovery , 2012, Acta Pharmacologica Sinica.

[45]  G. Nikkhah,et al.  BRAF Activation Induces Transformation and Then Senescence in Human Neural Stem Cells: A Pilocytic Astrocytoma Model , 2011, Clinical Cancer Research.

[46]  David T. W. Jones,et al.  An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. , 2011, The Journal of clinical investigation.

[47]  Kirsten Schmieder,et al.  Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma , 2011, Acta Neuropathologica.

[48]  F. Fan,et al.  Luciferase Reporter Assay System for Deciphering GPCR Pathways , 2010, Current chemical genomics.

[49]  Peter J Houghton,et al.  Initial testing (stage 1) of AZD6244 (ARRY‐142886) by the pediatric preclinical testing program , 2010, Pediatric blood & cancer.

[50]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[51]  M. Belvin,et al.  RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth , 2010, Nature.

[52]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[53]  M. Pawlita,et al.  High-throughput detection and multiplex identification of cell contaminations , 2009, Nucleic acids research.

[54]  C. Sander,et al.  V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway , 2009, Proceedings of the National Academy of Sciences.

[55]  David T. W. Jones,et al.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. , 2008, Cancer research.

[56]  A. Poretti,et al.  Outcome of children with low-grade cerebellar astrocytoma: long-term complications and quality of life , 2008, Child's Nervous System.

[57]  Y. Yonekawa,et al.  A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. , 2003, Journal of neurosurgery.

[58]  Brian S. Yandell,et al.  Practical Data Analysis for Designed Experiments , 1998 .

[59]  A. Nordheim,et al.  Activation of ternary complex factor Elk‐1 by MAP kinases. , 1993, The EMBO journal.

[60]  C. Stiles,et al.  Dual control of cell growth by somatomedins and platelet-derived growth factor. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[62]  Armando Santoro,et al.  Sorafenib: a review of its use in advanced hepatocellular carcinoma. , 2009, Drugs.